Advertisement

Risikofaktor Homocystein

  • Verena Drebing
Chapter

Zusammenfassung

Homocysteln wird mittlerweile international als Risikofaktor für Herz-Kreislauf-Erkrankungen angesehen — sogar die New York Times berichtete im Juni 2000 über diese Substanz, die in ihrer Bedeutung in etwa dem Cholesterin gleichzusetzen ist. Erhöhte Homocystein-Werte können klar mit einem größeren Rlsiko für Herzinfarkte und arteriosklerotische Veränderungen in Zusammengang gebracht werden. Und auch bel einigen anderen Erkrankungen gilt Homocystein als valider Indikator. Als präventive Maßnahme hat sich vor allem die Gabe von Folsäure und Vitamin B12 bewährt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    McCully KS: Vascular pathology of homocysteinamia. Am J. Pathol. 1969; 56: 111–123 PubMedGoogle Scholar
  2. [2]
    Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHF, Bromberg IL, Cerone R, Fowler B, Gröbe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cysthatione b-synthase deficiency. Am J Hum Genet 1985; 37:1–31. PubMedCentralPubMedGoogle Scholar
  3. [3]
    Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocysteine levels in men with premature coronary artery disease. J. Am. Coll. Cardiol. 1990; 16: 1114–1119 PubMedCrossRefGoogle Scholar
  4. [4]
    Graham IM. Plasma Homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775–1781. PubMedCrossRefGoogle Scholar
  5. [5]
    J. Perry et al.: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged british men. Lancet 1995; 346:1395–8. PubMedCrossRefGoogle Scholar
  6. [6]
    Selhub S, Jacques PF, Bostom AG, D’Agostino RB, Wilson PWF, Belanger AJ, O’Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. New M. J. Med. 1995; 332: 286–91. CrossRefGoogle Scholar
  7. [7]
    Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877–81. PubMedCrossRefGoogle Scholar
  8. [8]
    Taylor LM, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease. J Vase Surg 1991; 13:128–36 CrossRefGoogle Scholar
  9. [9]
    Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–6. PubMedCrossRefGoogle Scholar
  10. [10]
    Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149–55. PubMedCrossRefGoogle Scholar
  11. [11]
    Miner SES, Evrovski J, Cole DEC. Clinical Chemistry and Molecular Biology of Homocysteine Metabolism: An Update. Clinical Biochemistry. 1997; 30: 189–201. PubMedCrossRefGoogle Scholar
  12. [12]
    McCully KS. Homocysteine and vascular disease. Nature Medicine 1996; 2: 386–389. PubMedCrossRefGoogle Scholar
  13. [13]
    Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Eng J Med 1998; 338: 1042–50. CrossRefGoogle Scholar
  14. [14]
    de Groot PG, Willems C, Boers GHJ, Gonsalves MD, van Aken WG, van Mourik JA. Endothelial cell dysfunction in homocystinuria. European Journal of Clinical Investigation 1983; 13: 405–10. PubMedCrossRefGoogle Scholar
  15. [15]
    Harker LA, Ross R, Slichter S, Scott CR. Homocysteine-induced arteriosclerosis. The Journal of Clinical Investigation 1976; 58: 731–41. PubMedCentralPubMedCrossRefGoogle Scholar
  16. [16]
    Tsai J-C, Perrella MA, Yoshizumi M, Hsieh C-M, Haber E, Schlegel R, Lee M-E. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369–73. PubMedCrossRefGoogle Scholar
  17. [17]
    Welch GN, Upchurch G, Loscalzo J. Hyperhomocysteinemia and atherothrombosis, Ann N Y Acad Sci 1997; 811: 48–58. PubMedCrossRefGoogle Scholar
  18. [18]
    Kang SS, Wong PWK, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Annu Rev. Nutr. 1992; 12:279–298. PubMedCrossRefGoogle Scholar
  19. [19]
    C.S. Berwanger et al.: Homocysteine and vascular disease. British Journal of Surgery. 1995; 82: 726–731. PubMedCrossRefGoogle Scholar
  20. [20]
    Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in elderly patients. JAMA 1993; 270: 2693–98. PubMedCrossRefGoogle Scholar
  21. [21]
    Cravo ML, Gloria LM, Selhub J, Nadeau MR, Camilo ME, Resende MP, Cardoso JN, Leitao CN, Mira FC. Hyperhomocystei-nemia in chronic alcoholism: correlation with folate, vitamin B-12 and vitamin B-6 status. Am J Clin Nutr 1996; 63:220–224. PubMedGoogle Scholar
  22. [22]
    Refsum H, Ueland, Nygard O, Vollset SE.: Homocysteine and cardiovascular disease. Annu. Rev. Medicine 1998; 49:31–62. CrossRefGoogle Scholar
  23. [23]
    Ueland PM, Refsum H: Plasma homocysteine, a risk for vascular disease: plasma levels in health, disease, and drug therapy. J. Lab. Clin. Med. 1989; 114: 473–501 PubMedGoogle Scholar
  24. [24]
    Mueller F, Svardal AM, Aukrust P, Berge RK, Ueland PM, Froland SS. Elevated plasma concentration of reduced homocysteine in patients with human immunodeficiency virus infection. Am. J. Clin. Nutr. 1996; 63:242–248. Google Scholar
  25. [25]
    Bergmark C, Mansoor MA, Svardal A, de Faire U. Redox Status of Plasma Homocysteine and Related Aminothiols in Smoking and Nonsmoking Young Adults. Clin. Chem. 1997; 43:1997–1999. PubMedGoogle Scholar
  26. [26]
    Koch HG. Störungen im Stoffwechsel des Homocysteins. Sonderdruck Orphan Europe, 1999 Google Scholar
  27. [27]
    Schreiner R, Göbel-Schreiner B, Walch S. Homocystein: Biochemie und klinische Bedeutung. Clin Lab 1995; 41: 1007–1012. Google Scholar
  28. [28]
    Ueland PM, Refsum H, Brattström L. Plasma homocystein and cardiovascular disease. In: Boyer Francis R. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker, 1992; 182–236. Google Scholar
  29. [29]
    Schreiner R, Göbel-Schreiner B, Durst C, Casper R, Walch S. Homocysteine: reference values. Clin. Lab. 1997; 43: 1121–1124. Google Scholar
  30. [30]
    Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney International 1997; 52: 10–20. PubMedCrossRefGoogle Scholar
  31. [31]
    Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease. JAMA 1995; 274: 1049–1057 PubMedCrossRefGoogle Scholar
  32. [32]
    Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplements. Clin. Investig. 1993; 71: 993–998. PubMedCrossRefGoogle Scholar
  33. [33]
    Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Eng] Med 1998; 338: 1009–15. CrossRefGoogle Scholar
  34. [34]
    Rasmussen K, Moller J, Lyngbak M, Holm-Pedersen A, Dybkar L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996; 42: 630–636. PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • Verena Drebing

There are no affiliations available

Personalised recommendations